RT Journal Article
SR Electronic
T1 Variant abundance estimation for SARS-CoV-2 in wastewater using RNA-Seq quantification
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.31.21262938
DO 10.1101/2021.08.31.21262938
A1 Jasmijn A. Baaijens
A1 Alessandro Zulli
A1 Isabel M. Ott
A1 Mary E. Petrone
A1 Tara Alpert
A1 Joseph R. Fauver
A1 Chaney C. Kalinich
A1 Chantal B.F. Vogels
A1 Mallery I. Breban
A1 Claire Duvallet
A1 Kyle McElroy
A1 Newsha Ghaeli
A1 Maxim Imakaev
A1 Malaika Mckenzie-Bennett
A1 Keith Robison
A1 Alex Plocik
A1 Rebecca Schilling
A1 Martha Pierson
A1 Rebecca Littlefield
A1 Michelle Spencer
A1 Birgitte B. Simen
A1 Yale SARS-CoV-2 Genomic Surveillance Initiative
A1 William P. Hanage
A1 Nathan D. Grubaugh
A1 Jordan Peccia
A1 Michael Baym
YR 2021
UL http://medrxiv.org/content/early/2021/09/02/2021.08.31.21262938.abstract
AB Effectively monitoring the spread of SARS-CoV-2 variants is essential to efforts to counter the ongoing pandemic. Wastewater monitoring of SARS-CoV-2 RNA has proven an effective and efficient technique to approximate COVID-19 case rates in the population. Predicting variant abundances from wastewater, however, is technically challenging. Here we show that by sequencing SARS-CoV-2 RNA in wastewater and applying computational techniques initially used for RNA-Seq quantification, we can estimate the abundance of variants in wastewater samples. We show by sequencing samples from wastewater and clinical isolates in Connecticut U.S.A. between January and April 2021 that the temporal dynamics of variant strains broadly correspond. We further show that this technique can be used with other wastewater sequencing techniques by expanding to samples taken across the United States in a similar timeframe. We find high variability in signal among individual samples, and limited ability to detect the presence of variants with clinical frequencies <10%; nevertheless, the overall trends match what we observed from sequencing clinical samples. Thus, while clinical sequencing remains a more sensitive technique for population surveillance, wastewater sequencing can be used to monitor trends in variant prevalence in situations where clinical sequencing is unavailable or impractical.Competing Interest StatementN.D.G. is an infectious diseases consultant for Tempus Labs. W.P.H. is a scientific advisory board member to Biobot Analytics and has received compensation for expert witness testimony on the expected course of the pandemic. N.G. is co-founder of Biobot Analytics; C.D., K.A.M., and M.I. are employees of Biobot Analytics.Funding StatementThis work was supported in part by the Pew Charitable Trusts, the David and Lucile Packard Foundation, NIH NIGMS award R35GM133700, and the Alfred P. Sloan Foundation (J.A.B. and M.B); CTSA Grant Number TL1 TR001864 (M.E.P. and T.A.); Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (N.D.G.); CDC Contract #75D30120C09570 (N.D.G.); Yale CoReCT pilot award (J.P. and N.D.G.); and NIH NIGMS award U54GM088558 (W.P.H.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board from the Yale University Human Research Protection Program determined that the RT-qPCR testing and sequencing of de-identified remnant COVID-19 clinical samples obtained from clinical partners conducted in this study is not research involving human subjects (IRB Protocol ID: 2000028599).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw SARS-CoV-2 sequencing data from New Haven wastewater (.fastq files) are available on NCBI SRA under Bioproject PRJNA741211. The clinical sequencing data can be accessed via covidtrackerct.com. The raw SARS-CoV-2 sequencing data from across the U.S. (.fastq files) are available on NCBI SRA under Bioproject PRJNA759260. The simulated wastewater sequencing data (.fastq files) for benchmarking are available on Zenodo (DOI: 10.5281/zenodo.5307070). https://www.ncbi.nlm.nih.gov/bioproject/PRJNA741211 https://www.ncbi.nlm.nih.gov/bioproject/PRJNA759260 https://zenodo.org/record/5307070#.YS6eZNNKjUI